1. Etiocholanolone was employed in the assessment of bone marrow granulocyte reserves in a group of patients with acute leukemia prior to the administration of therapy.

2. Normal levels of circulating white blood cells and granulocytes and/or remission bone marrow status were often associated with abnormal test responses.

3. Individuals having a positive test response experienced significantly less hematologic toxicity following therapy than did those patients having a negative response.

4. Etiocholanolone proved to be a safe agent without significant side effects.

5. This test can be helpful in the prediction of toxicity following antileukemic therapy.

This content is only available as a PDF.
© 1968 by American Society of Hematology, Inc.
1968
Sign in via your Institution